SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in the Piper Sandler
Weill Cornell Medicine Researchers Utilize Fluidigm Hyperion Imaging System to Identify a Phenotype of Immune Cell Activity Distinct from Other Lung Infections A Framework for Data-Driven Spatial Understanding of Lung Pathology to Inform New Treatment Approaches for COVID-19 SOUTH SAN FRANCISCO,
SOUTH SAN FRANCISCO, Calif. , Nov. 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local
SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and
Third Q uarter T otal R evenue I n creased 50 P ercent to $ 39 .9 M illion Third Q uarter P roduct and Service R evenue I ncreased 34 P ercent to $35 . 3 M illion D riven by COVID-19 T esting GAAP N et L oss in the T hird Q uarter Was $6.0 M illion ; Non-GAAP N et I ncome W as $2.5
Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
25 Trials Utilizing Mass Cytometry Initiated in 2020 SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass
Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution Fluidigm Powered Testing Service to be Rolled Out in Seven European Countries SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Fluidigm COVID-19 Campus Safeguard Program Improves Availability of Non i nvasive, Saliva-Based SARS-CoV-2 Test s for Higher Education Institutions High-Throughput , Integrated Testing Platform and Reliable Supply Chain SOUTH SAN FRANCISCO, Calif. , Oct.
SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2020 financial results on Thursday,
